Mumbai, Aug. 19 -- The product is bioequivalent and therapeutically equivalent to the reference listed drug Mycamine for Injection, 50 mg/vial and 100 mg/vial, originally developed by Astellas Pharma US, Inc. The company will begin distribution in September 2025.

According to IQVIA sales data for the 12-month period ending June 2025, the U.S. market for Mycamine for Injection generated annual sales of approximately $60.7 million.

Micafungin is an echinocandin antifungal used primarily in the treatment of candidemia, esophageal candidiasis, and for prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.

Marc Kikuchi, president & business head, North America said, "We are excited to announce the ...